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Abstract
Background: Although guidelines for the care of the dying patient exist the evidence base to
support the guidelines is poor. Some of the factors contributing to this include failure to recruit to
trials, protective healthcare professionals and subsequent attrition from trials due to the death of
the patients. Recent studies report favourably on the use of cluster randomisation as an
appropriate methodology for use in this patient group.
Methods/design:  A feasibility study, exploring two types of randomisation as appropriate
methodology for trials involving dying patients. Cluster randomisation and randomised consent will
be utilised following a crossover design at two sites, one oncology ward and one Macmillan unit
within the Northwest Wales NHS Trust. All patients commencing on the Integrated Care Pathway
(ICP) for the Last Days of Life will be eligible for inclusion in the study. Using the hypothesis that
it is not necessary to prescribe an anti-emetic medication when setting up a syringe driver for the
dying patient, the study will evaluate different models of research methodology.
Discussion: The identification of the most appropriate methodology for use in studies concerning
this patient group will inform the development of future clinical studies. Furthermore, the
outcomes of this feasibility study will inform the development, of a proposal seeking funding for
Wales-wide trials in palliative care. The identification of an appropriate methodology will provide
a starting point for the establishment of a robust evidence base for the care of the dying patient.
Background
Designing trials involving dying patients can be fraught
with methodological issues and ethical considerations
since this is a vulnerable patient group [1,2]. Within palli-
ative care there is a significant lack of research evidence
with respect to the treatment and care of the dying patient
[3]. Previous studies [4] have detailed inherent difficulties
in carrying out methodologically sound research at the
end of life. Difficulties recruiting to trials are documented,
[5] and attrition from trials due to death is recognised as
problematic [6].
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Guidelines for the care of the dying patient exist, [7] how-
ever, the evidence base to support the guidelines is poor.
In England the implementation of the Liverpool inte-
grated care pathway for the last two days of life has facili-
tated the production of data for research and audit
purposes [8]. The Wales-wide implementation of an inte-
grated care pathway (ICP) for the last two days of life has
facilitated local and national benchmarking exercises [9].
Analysis of 2500 variance sheets from patients dying on
the ICP across Wales indicates that, there is little evidence
to support the routine use of anti-emetic medication in
syringe drivers for dying patients. Furthermore, the inclu-
sion of an anti-emetic in the syringe driver in combination
with other medications can result in crystallisation [10]
consequently, the medications may not be safely and effi-
ciently delivered to the patient.
Recent studies seeking to investigate an intervention in
palliative care report favourably on the use of a cluster
randomised design as an alternative method for establish-
ing evidence of effectiveness in this specific patient group
[11]. Utilising the cluster randomisation methodology,
consent can be sought at cluster level through the appoint-
ment of a cluster gatekeeper [12]. The cluster guardian wit-
nesses the cluster consent given by the gatekeeper and
holds a supervisory role for the duration of the study.
Both the cluster gatekeeper and the cluster guardian must
be independent of the research team. The cluster gate-
keeper may after due consideration and consultation with
the cluster guardian withdraw the cluster from the study.
Randomised or Zelen consent hereafter referred to as "
Zelen" [13] as an alternative methodology seeks informed
consent at the onset of treatment and after randomisation
if the patient is to receive the experimental treatment.
Patients consenting to the trial treatment have the right to
withdraw from the trial at any time.
One of the main criticisms of Zelen's method is that a con-
sideration of sample size needs to be undertaken if the
study is not to be undermined by patients opting out, or
declining to be recruited [14,15]. There are specific ethical
issues associated with the design and conduct of Zelen tri-
als [16]. Collaboration between palliative care researchers
and ethics committees to develop palliative care studies is
advocated in the literature [17]. This paper outlines a fea-
sibility study to explore cluster randomisation and ran-
domised consent as viable methodology for future trials
involving dying patients. The study will take place over
one year in two sites, one oncology ward and one Macmil-
lan unit within the Northwest Wales NHS Trust and
employ a crossover design. The outcomes of the study will
inform the development of a full proposal to undertake a
Wales-wide trial seeking collaboration with the Welsh
Cancer Trials Network and the National Cancer Research
Institute.
Method
Ethical approval for this feasibility study was granted by
the North Wales Health Authority Research Committee
(West, Central and East sub-committees).
Two sites will participate in the study, an oncology ward
in a local district general hospital, and the Macmillan unit
in a local community hospital. The two sites will be ran-
domly allocated to begin the study with either the Zelen
method or the cluster randomisation method, allocation
will be undertaken independently and from a distance by
the University of Wales Bangor. On admission to either
ward on each site patients will be approached for consent
to use their medical data (See additional file 1).
Zelen method
The procurement of informed consent from the dying
patient to participate in a palliative care trial will be
approached pragmatically. The design of the trial necessi-
tates that informed consent is required in those patients
randomised to the experimental arm of the study only. At
the commencement of the syringe driver, the patient in
the experimental arm of the study will be informed of the
procedure to omit the anti-emetic from the syringe driver
(See additional file 2), and invited to give written consent
to participate in the study (See additional file 3). The
patient will be reassured that if they vomit or feel at all
nauseous an anti-emetic will be available and adminis-
tered. The patient will also be made aware that if at any
time they wish to withdraw from the study they are free to
do so with no repercussions for their care or comfort.
Participation in the trial entails minimal risk to the patient
and endeavours to reduce the pharmacological burden on
the dying patient. Furthermore, the omission of an anti-
emetic in the syringe driver may result in enhanced safety
and efficiency of medication delivery.
Cluster randomisation
Consent for inclusion in the cluster randomisation trial
will be sought at cluster level rather than on an individual
basis. As a cluster representation mechanism (CRM) a
cluster gatekeeper will be designated. The cluster gate-
keeper will be informed by letter of the study aims and
methods and invited to act as cluster gatekeeper (See addi-
tional file 4). As cluster gatekeeper the designated health-
care professional will be responsible for 'assenting' his/her
cluster to the trial (See additional file 5). The cluster gate-
keeper provides informed assent for the cluster to partici-
pate in the study or trial. The cluster guardian is informed
of the study and is recruited from management within the
North West Wales NHS Trust. After due consideration andBMC Palliative Care 2004, 3 http://www.biomedcentral.com/1472-684X/3/1
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consultation with the cluster guardian, the gatekeeper
may withdraw the cluster from the trial. Any instances of
withdrawal will be fully documented and reported.
There are two sites or clusters in this study therefore, two
cluster gatekeepers will be appointed. The cluster gate-
keepers can be appointed from key nursing or medical
staff at the two sites, but must be independent of the
research team. The cluster gatekeepers are responsible to
the cluster in the first instance and answerable to the clus-
ter guardians.
The cluster guardians will be drawn from management
within the Northwest Wales NHS Trust. Management staff
at both sites will be contacted by letter and informed of
the study, the same letter will carry an invitation to act as
cluster guardian for the duration of the study (See addi-
tional file 6). The cluster guardians will witness the cluster
assent given by the cluster gatekeepers. The cluster guard-
ians must be independent of the research team.
This study is an exploration of cluster randomisation and
Zelen as an appropriate methodology for studies involv-
ing dying patients and does not on this occasion seek to
reach statistical significance with any outcomes of the
study. To the same end, the sample sizes and subsequent
power of the design are not of primary concern, the main
issue of interest in this study is the appropriateness of the
methodology for further studies in palliative care. How-
ever, it is expected that the study will highlight any inher-
ent difficulties in recruiting to trial and identify the
potential flaws in achieving optimum sample size for the
study design.
It will be important to inform palliative care staff at the
two participating sites as to the nature of the trial (See
additional file 7). Prior to the onset of the active phase of
the study, a baseline assessment of the use of anti-emetic
medications in syringe drivers, for patients on the inte-
grated care pathway for the last days of life will be under-
taken.
The project nurse will give a general introduction to the
study at both sites and after each site has been randomised
to one of the two methods, the project nurse will then re-
visit each site and give a more specific presentation regard-
ing the methodology. Handouts of the presentations will
be left with staff at both sites and three months later
repeated when the two sites swap methodologies. To
maintain consistency in the way that the two sites are
introduced to the study and the different methods, a
"script" will be developed and used as a framework for the
presentations.
Two hospital sites with palliative care beds within the
Northwest Wales NHS Trust will be randomly allocated
one of two methodological conditions, cluster randomi-
sation or Zelen. Both sites will have two treatment condi-
tions, to routinely prescribe an anti-emetic at the
commencement of a syringe driver for a dying patient, the
usual procedure, or to change practice and not prescribe
an anti-emetic when commencing on a syringe driver.
However, if the patient experiences nausea or vomiting
then medication will be available and administered
immediately. With respect to the Zelen method, the
patient is randomised to the experimental treatment
(Condition A) through the use of a "Decision Tree" (See
additional file 8).
Each site will continue with the designated methodology
for three months, the project nurse will regularly visit each
site and request the medical notes of each patient dying
on the care pathway. At the end of a three-month period,
the project nurse will hold a 'de-briefing' session at each
site, prior to introducing the new method for the next
three months. After three months the methodology at the
two sites will be switched or crossed over so that site one,
previously employing cluster randomisation as a method-
ology will now be utilising Zelen and vice versa (See addi-
tional file 9). Each site will be monitored to assess
progress, and to identify any difficulties in adhering to the
study protocol. Patients who have been prescribed anti-
emetics in the immediate period prior to the commence-
ment of a syringe driver, will form a sub-set of the study.
Both sites will record any variances to the agreed course of
care on the pathway variance sheet.
Outcomes
After a trial of each method for three months at each site,
the appropriateness of cluster randomisation and Zelen as
a methodology for trials in palliative care will be exam-
ined and the facilitators and inhibitors identified. The rate
of refusal to recruit to the new treatment in the Zelen
model is an issue raised in the literature [14,15].
Considerations will be given to issues of sample size and
statistical power to inform the development of prospec-
tive studies. Further evaluation of the variance report as a
tool for obtaining detailed information from the ICP will
be undertaken.
The variance reports will be analysed and compared, to
establish if there is any clear evidence to support the ces-
sation of routine prescribing of anti-emetic medication in
syringe drivers for dying patients.
Combinations of analgesics and anti-emetics can precipi-
tate in syringe drivers causing administrative errors and
inadequate periods of analgesia. Exploring the necessityBMC Palliative Care 2004, 3 http://www.biomedcentral.com/1472-684X/3/1
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of routine prescribing of anti-emetics in syringe drivers
could reduce the pharmacological burden on the dying
patient and improve the safety and efficiency with which
medications are delivered to the patient.
Explorations of Zelen and cluster randomisation, as
appropriate methods for future studies involving dying
patients are important. At present the evidence base for
the care of this specific patient group is poor. The identifi-
cation of the most appropriate methodology for use in
studies concerning this patient group will inform the
development of future clinical studies.
An identification of the factors contributing to attrition
rates in a study concerning dying patients will be valuable.
The outcomes of this feasibility study will inform future
studies about the sample size needed to reach statistical
power for this particular research design and the specific
patient population.
The utility of the variance sheet as a data-reporting tool
within a trial environment will be explored.
Furthermore, the outcomes of this feasibility study will
inform the development, of a proposal seeking funding
for Wales-wide trials in palliative care. The identification
of an appropriate methodology will provide a starting
point for the establishment of a robust evidence base for
the care of the dying patient.
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